[1]陈晓宇,曾庆维,陈红林,等.子宫内膜癌组织中miR-3188和mTOR表达量与预后的相关性研究[J].现代检验医学杂志,2021,36(06):17-21.[doi:10.3969/j.issn.1671-7414.2021.06.004]
 CHEN Xiao-yu,ZENG Qing-wei,CHEN Hong-lin,et al.Study on the Correlation between the Expression Levels of miR-3188 and mTOR in Endometrial Cancer and the Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(06):17-21.[doi:10.3969/j.issn.1671-7414.2021.06.004]
点击复制

子宫内膜癌组织中miR-3188和mTOR表达量与预后的相关性研究()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年06期
页码:
17-21
栏目:
论 著
出版日期:
2021-12-15

文章信息/Info

Title:
Study on the Correlation between the Expression Levels of miR-3188 and mTOR in Endometrial Cancer and the Prognosis
文章编号:
1671-7414(2021)06-017-05
作者:
陈晓宇曾庆维陈红林
(1.开滦总医院林西医院,河北唐山 063000;2.唐山市妇幼保健院,河北唐山 063000)
Author(s):
CHEN Xiao-yu ZENG Qing-wei CHEN Hong-lin et al
(1. Linxi Hospital of Kailuan General Hospital, Hebei Tangshan 063000, China; 2. Tangshan Maternity and Child Health Hospital, Hebei Tangshan 063000, China)
关键词:
子宫内膜癌微小核糖核酸-3188雷帕霉素靶蛋白
分类号:
R737.33;R730.43
DOI:
10.3969/j.issn.1671-7414.2021.06.004
文献标志码:
A
摘要:
目的 探究子宫内膜癌(endometrial carcinoma, EC)组织中微小核糖核酸-3188(miR-3188)和雷帕霉素靶蛋白(mTOR)表达量与预后的相关性。方法 前瞻性选取2016年1月至2018年4月在开滦总医院林西医院接受手术治疗的121例EC患者作为研究对象,并根据3年内是否复发将其分为复发组(n=32)和未复发组(n=89)。用实时荧光定量PCR法检测EC组织和癌旁组织中miR-3188表达量,用蛋白质免疫印迹法检测EC组织和癌旁组织中mTOR表达量。结果 EC组织中miR-3188相对表达量低于癌旁组织(0.60±0.14 vs 1.46±0.14),EC组织中mTOR相对表达量高于癌旁组织(0.92±0.11比0.63±0.11),差异均有统计学意义(t=48.995,19.348,均P=0.000)。不同浸润深度、是否淋巴结转移、是否子宫外转移、不同分化程度及不同FIGO分期的miR-3188和mTOR相对表达量比较,差异均有统计学意义(t=2.400~8.611,均P<0.05)。未复发组的miR-3188相对表达量高于复发组(0.66±0.11 vs 0.45±0.08),mTOR相对表达量低于复发组(0.88±0.10 vs 1.02±0.06),差异均有统计学意义(t=11.220,9.229,均P=0.000)。COX回归分析结果显示分化程度高(HR=0.696,P=0.015)、miR-3188表达量高(HR=0.058,P=0.008)是EC预后的独立保护因素,FIGO分期高(HR=2.967,P=0.000)、mTOR表达量高(HR=1.162,P=0.035)是EC预后的独立危险因素。Pearson相关分析结果显示EC组织中miR-3188相对表达量与mTOR相对表达量呈负相关关系(r=-0.409,P=0.000)。结论 EC组织中miR-3188表达量低、mTOR表达量高与预后不良有关。
Abstract:
Objective To explore the correlation between the expression of microRNA-3188 (miR-3188), mammalian target of rapamycin (mTOR) in endometrial carcinoma (EC) and the prognosis. Methods A total of 121 patients with EC who received surgical treatment in Linxi Hospital of Kailuan General Hospital from January 2016 to April 2018 were prospectively selected and divided into relapsed group (n=32) and non-relapsed group (n=89) according to recurrence within 3 years. Real-time fluorescence quantitative PCR was used to detect the expression of miR-3188 in EC tissues and adjacent tissues, and Western blotting was used to detect the expression of mTOR in EC tissues and adjacent tissues. Results The relative expression of miR-3188 in EC tissue was lower than that in adjacent tissues (0.60±0.14 vs 1.46±0.14), and the relative expression of mTOR in EC tissue was higher than that in adjacent tissues (0.92±0.11 vs 0.63±0.11), the differences were statistically significant (t=48.995, 19.348, all P=0.000). The relative expression levels of miR-3188 and mTOR were compared with different depth of invasion, lymph node metastasis, extrauterine metastasis, different degree of differentiation, and different FIGO stages, and the differences were statistically significant (t=2.400~8.611, all P<0.05). The relative expression of miR-3188 in the non-relapsed group was higher than that in the relapsed group (0.66±0.11 vs 0.45±0.08), and the relative expression of mTOR was lower than that in the relapsed group (0.88±0.10 vs 1.02±0.06), the differences were statistically significant (t=11.220, 9.229, all P=0.000). COX regression analysis showed that high degree of differentiation (HR=0.696, P=0.015) and high expression of miR-3188 (HR=0.058, P=0.008) were independent protective factors for the prognosis of EC, and high FIGO staging (HR=2.967, P=0.000) and high expression of mTOR (HR=1.162, P=0.035) were independent risk factors for the prognosis of EC. The results of Pearson correlation analysis showed that the relative expression of miR-3188 in EC tissues was negatively correlated with the relative expression of mTOR (r=-0.409, P=0.000). Conclusion Low expression of miR-3188 and high expression of mTOR in EC tissues are related to poor prognosis.

参考文献/References:

[1] BROOKS R A, FLEMING G F, LASTRA R R, etal. Current recommendations and recent progressin endometrial cancer[J]. CA-A Cancer Journal forClinicians, 2019, 69(4): 258-279.
[2] 高玉霞, 董学彩, 王文翔, 等. 长链非编码RNAHOTTIP 在子宫内膜癌患者组织中的表达及其临床意义[J]. 中国肿瘤生物治疗杂志, 2020, 27(12):1378-1382.GAO Yuxia, DONG Xuecai, WANG Wenxiang, et al.Expression and clinical significance of long non-codingRNA HOTTIP in tissues of patients with endometrialcarcinoma [J]. Chinese Journal of Cancer Biotherapy,2020, 27(12):1378-1382.
[3] 曾庆维.mTOR,HIF-1α 和IL-17 在子宫内膜癌中的表达及临床意义[D]. 河北唐山: 华北理工大学,2018.ZENG Qingwei. The expression of mTOR, HIF-1α and IL-17 in endometrial carcinoma and theirclinical significance [D]. Hebei Tangshan: North ChinaUniversity of Technology, 2018.
[4] RAI R, ESSEL K G, BENBROOK D M, et al.Preclinical efficacy and involvement of AKT, mTOR,and ERK kinases in the mechanism of sulforaphaneagainst endometrial cancer[J]. Cancers, 2020, 12(5):1273.
[5] MOHANKUMAR K, LI Xi, SRIDHARAN S, et al.Nuclear receptor 4A1 (NR4A1) antagonists induceROS-dependent inhibition of mTOR signaling inendometrial cancer[J]. Gynecologic Oncology, 2019,154(1): 218-227.
[6] ZHAO Mengyang, LUO Rongcheng, LIU Yiyi, etal. miR-3188 regulates nasopharyngeal carcinomaproliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN[J]. Nature Communications, 2016, 7(1):563-568.
[7] WANG Chunyan, LIU Enqi, LI Wen, et al. MiR-3188inhibits non-small cell lung cancer cell proliferationthrough FOXO1-mediated mTOR-p-PI3K/AKT-c-JUNsignaling pathway[J]. Frontiers in Pharmacology, 2018,9: 1362.
[8] WANG Xiaoning, QIN Xing, YAN Ming, et al. Loss ofexosomal miR-3188 in cancer-associated fibroblasts contributesto HNC progression[J]. Journal of Experimental& Clinical Cancer Research, 2019, 38(1): 151.
[9] XU Mingxi, GU Meng, ZHOU Juan, et al. Interactionof YAP1 and mTOR promotes bladder cancerprogression[J]. International Journal of Oncology,2020, 56(1): 232-242.
[10] MATSUBARA S, MABUCHI S, TAKEDA Y, et al.Prognostic value of pre-treatment systemic immuneinflammationindex in patients with endometrialcancer[J]. PLoS One, 2021, 16(5): e0248871.
[11] 陈丽华, 朱婕曼, 刘玉凤, 等. 子宫内膜癌组织中血管紧张素(1-7) 及线粒体组装受体水平表达与临床病理特征的相关性[J]. 现代检验医学杂志, 2021,36(2):24-27.CHEN Lihua, ZHU Jieman, LIU Yufeng, et al.Correlation between the expression of angiotensin(1-7) and mitochondrial assembled receptors andclinicopathological characteristics in endometrialcancer [J]. Journal of Modern Laboratory Medicine,2021, 36(2):24-27.
[12] JANUSZYK P, JANUSZYK K, WIERZBIKSTRO?SKAM, et al. Analysis of the differences in theexpression of mRNAs and miRNAs associated withdrug resistance in endometrial cancer cells treated withsalinomycin[J]. Current Pharmaceutical Biotechnology,2021, 22(4): 541-548.
[13] CHEN Xiaowen, CHEN Jianli. miR-3188 regulates cellproliferation, apoptosis, and migration in breast cancerby targeting TUSC5 and regulating the p38 MAPKsignaling pathway.[J]. Oncology Research, 2018, 26(3):363-372.
[14] ZHOU Shaojun, DENG Yueling, LIANG Huifang,et al. Hepatitis B virus X protein promotes CREBmediatedactivation of miR-3188 and Notch signalingin hepatocellular carcinoma[J]. Cell Death andDifferentiation, 2017, 24(9): 1577-1587.
[15] 曾庆维, 马思琪, 曲银娥, 等.mTOR, HIF-1a 和IL-17 在子宫内膜癌中表达情况的研究现状[J]. 中国煤炭工业医学杂志, 2017,20(5):617-619.ZENG Qingwei, MA Siqi, QU Yine, et al. Researchstatus of mTOR, HIF-1a and IL-17 expression inendometrial carcinoma[J]. Chinese Journal of CoalIndustry Medicine, 2017,20(5):617-619.
[16] EFSUN A S, CANACANKATAN N, G?RSES ?, etal. Relevance of lipogenesis and AMPK/Akt/mTORsignaling pathway in endometrial cancer[J]. EuropeanReview for Medical and Pharmacological Sciences,2021, 25(2): 687-695.
[17] JING Xuanxuan, PENG Jin, DOU Yu, et al. MacrophageERα promoted invasion of endometrial cancercell by mTOR/KIF5B-mediated epithelial to mesenchymaltransition[J]. Immunology and Cell Biology, 2019,97(6): 563-576.
[18] TORTORELLA L, RESTAINO S, ZANNONI G F, etal. Substantial lymph-vascular space invasion (LVSI)as predictor of distant relapse and poor prognosis inlow-risk early-stage endometrial cancer[J]. Journal ofGynecologic Oncology, 2021, 32(2): e11.
[19] YOKOI E, MABUCHI S, KOMURA N, et al. Incorporationof pretreatment leukocytosis and thrombocytosisinto the FIGO staging system for prognosis in surgicallytreated endometrial cancer[J]. International Journalof Gynaecology and Obstetrics, 2020, 151(2): 272-278.
[20] CHEN Hao, WU Qijun, ZHANG Yunzheng, et al.Nomograms based on the novel platelet index scorepredict postoperative prognosis in endometrial cancer[J].Gynecologic Oncology, 2020, 158(3): 689-697.

相似文献/References:

[1]李 玲a,罗雅文a,何 霞a,等.子宫内膜癌患者BMI与血清HE4,CA125联合检测的诊断价值[J].现代检验医学杂志,2018,33(05):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
 LI Linga,LUO Ya-wena,HE Xiaa,et al.Diagnostic Value of Combined Detection of Body Mass Index and Serum HE4,CA125 in Patients with Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(06):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
[2]李晓丽,胡陇娟.子宫内膜癌组织中长链非编码RNA ZEB1-AS1的表达与临床特征及对化疗药物耐药性研究[J].现代检验医学杂志,2019,34(04):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
 LI Xiao-li,HU Long-juan.Research on Expression and Clinical Characteristics of Long-Chain Non-Coding RNA ZEB1-AS1 in Endometrial Carcinoma and Resistance to Chemotherapy Drugs[J].Journal of Modern Laboratory Medicine,2019,34(06):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
[3]王娟,刘鑫,席稳燕.HMMR-AS1 在子宫内膜癌化疗耐药中的作用[J].现代检验医学杂志,2020,35(05):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
 WANG Juan,LIU Xin,XI Wen-yan.Effect of HMMR-AS1 on the Chemotherapy-Resistance of Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
[4]李功娟,张治洋,樊阳阳.FEZF1-AS1在子宫内膜癌中的表达及其与患者临床特征的相关性[J].现代检验医学杂志,2021,36(01):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
 LI Gong-juan,ZHANG Zhi-yang,FAN Yang-yang.Expression of FEZF1-AS1 in Endometrial Carcinoma and Its Correlation with Clinical Characteristics of Patients[J].Journal of Modern Laboratory Medicine,2021,36(06):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
[5]陈丽华,朱婕曼,刘玉凤,等.子宫内膜癌组织中血管紧张素~1-7及线粒体组装受体水平表达与临床病理特征的相关性[J].现代检验医学杂志,2021,36(02):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
 CHEN Li-hua,ZHU Jie-man,LIU Yu-feng,et al.Correlation between the Expression of Angiotensin (1-7) and Mitochondrial Assembled Receptors and Clinicopathological Characteristics in Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2021,36(06):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
[6]刘静雅,张海亮,李宝平,等.长链非编码 RNA SNHG1在子宫内膜癌中的表达及调控 PI3K/AKT信号通路的研究[J].现代检验医学杂志,2022,37(01):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
 LIU Jing-ya,ZHANG Hai-liang,LI Bao-ping,et al.Expression of Long Non-coding RNA SNHG1 in Endometrial Carcinoma and Its Regulation of PI3K/AKT Signaling Pathway[J].Journal of Modern Laboratory Medicine,2022,37(06):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
[7]彭 浩,张印星,谢 环.长链非编码RNA CDKN2BAS 在子宫内膜癌组织表达及其生物学功能研究[J].现代检验医学杂志,2023,38(03):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
 PENG Hao,ZHANG Yin-xing,XIE Huan.Expression and Biological Function of Long Non-coding RNA CDKN2BAS in Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(06):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
[8]梁燕茹,郑 瑜,李 倩.子宫内膜癌患者术前血清apo AI 和Apelin 水平检测对预测淋巴脉管间隙浸润风险的价值研究[J].现代检验医学杂志,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
 LIANG Yanru,ZHENG Yu,LI Qian.Value of Preoperative Serum Apo AI and Apelin Levels in Predicting the Risk of Lymph Node Vascular Space Infiltration in Patients with Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2023,38(06):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
[9]陆 瑞,郭红霞,吴苗苗,等.KIF18B 通过激活Wnt/β catenin 信号通路促进子宫内膜癌细胞增殖和转移的实验研究[J].现代检验医学杂志,2023,38(05):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]
 LU Rui,GUO Hongxia,WU Miaomiao,et al.Experimental Study of KIF18B Promoting Endometrial Cancer Cell Proliferation and Metastasis by Activating Wnt/β-catenin Signaling Pathway[J].Journal of Modern Laboratory Medicine,2023,38(06):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]
[10]柴 静,张家弘,李梦雪.子宫内膜癌组织中TMIGD2,TIGIT 的表达及其与临床病理特征的相关性研究[J].现代检验医学杂志,2023,38(06):87.[doi:10.3969/j.issn.1671-7414.2023.06.016]
 CHAI Jing,ZHANG Jiahong,LI Mengxue.Expression of TMIGD2 and TIGIT in Endometrial Cancer Tissue and Their Correlation with Clinical Pathological Features[J].Journal of Modern Laboratory Medicine,2023,38(06):87.[doi:10.3969/j.issn.1671-7414.2023.06.016]

备注/Memo

备注/Memo:
基金项目:河北省卫健委医学科学研究课题计划(20191345)。作者简介:陈晓宇(1976-),男,本科,主管检验师,主治医师,主要从事妇科肿瘤治疗及科研工作,E-mail:caoml 1964@sina.com。通讯作者:曾庆雄(1978-),女,主要从事妇科肿瘤的治疗及科研工作,E-mial:78791529@qq.com。
更新日期/Last Update: 1900-01-01